Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.89 USD | +5.44% | +0.05% | -28.37% |
Apr. 15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
Financials (USD)
Sales 2024 * | 50.25M | Sales 2025 * | 52.42M | Capitalization | 2B |
---|---|---|---|---|---|
Net income 2024 * | -512M | Net income 2025 * | -523M | EV / Sales 2024 * | 25.6 x |
Net cash position 2024 * | 717M | Net cash position 2025 * | 991M | EV / Sales 2025 * | 19.3 x |
P/E ratio 2024 * |
-3.75
x | P/E ratio 2025 * |
-3.92
x | Employees | 526 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.63% |
Latest transcript on Intellia Therapeutics, Inc.
1 day | +5.44% | ||
1 week | -0.30% | ||
Current month | -20.88% | ||
1 month | -20.04% | ||
3 months | -16.86% | ||
6 months | -8.67% | ||
Current year | -28.62% |
Managers | Title | Age | Since |
---|---|---|---|
John Leonard
CEO | Chief Executive Officer | 66 | 14-06-30 |
Glenn Goddard
DFI | Director of Finance/CFO | 53 | 18-10-28 |
Eliana Clark
CTO | Chief Tech/Sci/R&D Officer | 67 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Cohen
BRD | Director/Board Member | 67 | 19-01-23 |
John Leonard
CEO | Chief Executive Officer | 66 | 14-06-30 |
Frank Verwiel
CHM | Chairman | 62 | 17-07-23 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.15% | 2 M€ | -25.75% | ||
4.87% | 1 M€ | 0.00% | - | |
4.17% | 1 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 21.82 | +5.13% | 931 250 |
24-04-26 | 20.76 | +3.70% | 1,025,682 |
24-04-25 | 20.02 | -5.43% | 1,460,292 |
24-04-24 | 21.17 | -1.67% | 859,470 |
24-04-23 | 21.53 | -1.37% | 849,473 |
Delayed Quote Nasdaq, April 29, 2024 at 10:21 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.62% | 2B | |
+2.36% | 42.75B | |
+47.75% | 41.61B | |
+12.37% | 41.34B | |
-12.36% | 26.59B | |
+8.51% | 25.49B | |
-23.43% | 18.12B | |
+30.52% | 12.24B | |
-1.77% | 11.76B | |
+8.40% | 11B |
- Stock Market
- Equities
- NTLA Stock